Home > Neurology > MS Virtual 2020 > Neuromyelitis Optica Spectrum Disorders > Satralizumab lowers risk of severe relapse in NMOSD patients

Satralizumab lowers risk of severe relapse in NMOSD patients


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
MS Virtual 2020
Trial
SAkuraSky, SAkuraStar
Patients treated with satralizumab had a 79% lower risk of severe relapse and were less likely to receive acute relapse therapy compared with placebo, in addition to having a lower relapse risk overall [1]. This was the main conclusion from a pooled analysis of results across the double-blind periods of two phase 3 trials, SAkuraSky and SAkuraStar. Satralizumab reduced relapse frequency and had a favourable safety profile in the placebo-controlled trials SAkuraSky (satralizumab + baseline immunosuppressants) and SAkuraStar (satralizumab monotherapy) trials. In both studies, participants were randomised to satralizumab 120 mg or placebo at weeks 0, 2, 4, and Q4W thereafter for 24 weeks....


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on